Lazertinib

The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the randomized phase 3 MARIPOSA trial.

In this video, Xiuning Le, MD, PhD, discusses some of the latest developments in the study and treatment of EGFR-mutated lung cancer.

In this edition, combination extends survival vs. standard first-line therapy, integrated care for smoking cessation during lung cancer screening and more.

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung cancer, according to the agents’ manufacturer.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, discusses the changing treatment landscape in EGFR-mutated lung cancer.

The FDA approved amivantamab-vmjw in combination with standard chemotherapy for the treatment of certain adults with non-small cell lung cancer, according to the agent’s manufacturer.

The FDA approved amivantamab-vmjw plus lazertinib as first-line treatment for certain adults with non-small cell lung cancer.

MADRID — Healio spoke with Hossein Borghaei, DO, MS, about the results of the MARIPOSA-2 trial, which were presented at ESMO Congress.

MADRID — In this video interview with Healio, Hossein Borghaei, DO, MS, talked about results from the MARIPOSA study presented at ESMO Congress.

MADRID — The combination of amivantamab and lazertinib improved PFS compared with osimertinib as first-line treatment for EGFR-mutated advanced non-small cell lung cancer, according to study results presented at ESMO Congress.